Bioscience

Insys a step closer to FDA approval

April 2, 2010

By Flinn Foundation

[Source: Phoenix Business Journal] – Insys Therapeutics Inc., a Phoenix bio­pharma­ceutical company developing products to help patients cope with cancer pain, has completed a successful Phase III clinical trial for its Fentanyl sublingual spray.

The spray targets breakthrough cancer pain, defined by intense bursts of pain throughout the day on top of the chronic discomfort cancer patients suffer. The trial showed the drug brought about effective pain relief within five minutes of being sprayed under the tongue. Fentanyl would supplement morphine and other analgesics used by cancer patients if it receives federal approval.

For more information: Insys a step closer to FDA approval